Supplemental Biologics License

FDA Accepts Eisai's Filing of a Supplemental Biologics License

FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease